期刊文献+

尼洛替尼的合成研究 被引量:5

Synthesis of Nilotinib
下载PDF
导出
摘要 3-乙酰基吡啶与N,N-二甲基甲酰胺二甲缩醛反应制得(E)-3-二甲胺基-1-(3-吡啶基)-2-丙烯-1-酮,接下来与硝酸胍环合得4-(3-吡啶基)-2-胺基嘧啶,然后与3-溴-4-甲基苯甲酸乙酯缩合再经水解反应制得关键中间体4-甲基-3-[[4-(3-吡啶基)-2-嘧啶基]胺基]苯甲酸。此关键中间体直接与3-三氟甲基-5-(4-甲基-1H-1-咪唑基)苯胺进行酰胺化反应,最终制得高选择性酪氨酸激酶抑制剂尼洛替尼,总收率约39.4%。 3-Acetylpyridine reacted with N,N-dimethylformamide dimethyl acetal to form(E)-3-dimethylamino-1-(pyridin-3-yl)prop-2-en-1-one,which was cyclized with guanidine nitrate to obtain 4-(pyridin-3-yl)-2-aminopyrimidine.4 was condensed with ethyl 3-bromo-4-methylbenzoate followed by hydrolysis to provide the key intermediate 4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzoic acid.Finally,6 was directly amidated with 3-trifluoromethyl-5-(4-methyl-1H-imidazol-1-yl)-benzenamine to achieve the highly selective inhibitor of tyrosine kinase,nilotinib with an overall yield of 39.4%.
出处 《化学试剂》 CAS CSCD 北大核心 2011年第3期266-268,共3页 Chemical Reagents
关键词 尼洛替尼 酪氨酸激酶抑制剂 抗白血病药 合成 nilotinib tyrosine kinase inhibitor antileukemia drug synthesis
  • 相关文献

参考文献10

  • 1PRENEN H, GUETENS G, BOECK G, et al. Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines[J]. Pharmacology,2006,77 : 11-16.
  • 2DE1NINGER M W. Nilotinib [ J ]. Clin. Cancer Res., 2008,14(13) :4 027-4 031.
  • 3杨建良.尼洛替尼:一种新的抗肿瘤靶向药物[J].癌症进展,2007,5(2):173-177. 被引量:9
  • 4DAVIES S L, SERRADELL N, BAYES M. Nilotinib[J]. Drugs Fur. ,2007,32( 1 ) : 17-25.
  • 5BREITENSTEIN W, FURET P, JACOB S,et al. Inhibitors of tyrosine kinases:WO ,2 004 005 281 [P]. 2004-01-15.
  • 6HUANG W S, SHAKESPEARE W C. An efficient synthesis of nilotinib ( AMN107 ) [ J ]. Synthesis, 2007, ( 14 ) : 2 121-2 124.
  • 7ZHANG R, LEI L, XU Y G, et al. Benzimidazol-2-yl or benzimidazol-2-yhhiomethyl benzoylguanidines as novel Na +/H + exchanger inhibitors,synthesis and protection against ischemie-reperfusion injury [ J ]. Bioorg. Med. Chem. Left. ,2007,17(9) .2 430-2 433.
  • 8ABEL S, ACEMOGLU M, ERB B, et al. Process for the synthesis of organic compounds : WO ,2 006 135 640[P]. 2006-12-21.
  • 9LIU Y F,WANG C L, BAI Y J, et al. A facile total synthesis of imatinib base and its analogues [J]. Org. Process. Res. Dev. ,2008,12(3) :490-495.
  • 10陈永江,王丽华,周红,王从站.尼罗替尼的合成[J].中国医药工业杂志,2009,40(6):401-403. 被引量:7

二级参考文献6

  • 1Talpaz M,Shah NP,Kantarjian H,菅鑫妍.Dasatinib用于治疗对伊马替尼耐药的Ph染色体阳性白血病[J].中国处方药,2006,5(8):60-60. 被引量:12
  • 2Deininger MW. Nilotinib [J]. Clin Cancer Res, 2008, 14(13): 4027-4031. (CA2009, 150: 15552)
  • 3Jabbour E, Cortes J, Kantarjian H, et al. Drug evaluation: Nilotinib---a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond [J]. Drugs, 2007, 10(7) : 468-479. (CA 2008, 149: 69381)
  • 4Huang WS, Shakespeare WC. An efficient synthesis of nilotinib (AMNI07) [J]. Synthesis, 2007, (14) : 2121-2124. (CA 2007, 147: 448724)
  • 5Werner B, Pascal F, Sandra J, et al. Inhibitors of protein kinases: US, 2008188451 [P]. 2008-08-07; WO, 2004005281 [P]. 2003-07-04. (CA 2004, 140: 77161)
  • 6Shieh WC, McKenna J. Process for the synthesis of 5- (methyl- 1H-imidazol- 1 -yl) -3- (trifluoromethyl) bene- zeneamine: US, 2008188656 [P]. 2008-08-07; WO, 2006135641 [P]. 2006-12-21. (CA2007, 146: 81883)

共引文献13

同被引文献34

  • 1杨建良.尼洛替尼:一种新的抗肿瘤靶向药物[J].癌症进展,2007,5(2):173-177. 被引量:9
  • 2Wang YL, Li J, Kansal VK, et al. Nilotinib intermediates andpreparation thereof: US, 2010 0016590 [P]. 2010-01-21.
  • 3Stephan A, Murat A, Bernhard E, et al Process for the synthesisof organic compounds: WO, 135640 [P], 2006-12-21.
  • 4Murat A, Berthold S, Shien WC, et al. Process for the synthesisof 5- (methyl-li/-imidazol-1 -yl) -3- (trifluoromethyl)-benzeneamine: WO, 2006 135619 [P]. 2006-12-21.
  • 5Breitenstein W,Furet P,Jacob S,et al.Inhibitors of tyrosine kinases:WO,2004005281[P].2004-01-15.
  • 6Ueda S,Su M,Buchwald SL,et al.Completely N1-selective palladium-catalyzed arylation of unsymmetric imidazoles:application to the synthesis of nilotinib[J].JAm Chem Soc,2012,134 (1):700-706.
  • 7Wang YL,Li J,Kansal VK,et al.Nilotinib intermediates and preparation thereof:WO,2010009402[P].2010-01-21.
  • 8Yeori A,Wang YL,Li J,et al.Preparation of nilotinib and intermediates thereof:WO,2010060074[P].2010-05-27.
  • 9Huang WS,Shakespeare WC.An efficient synthesis of nilotinib (AMN107)[J].Synthesis,2007,2007 (14):2121-2124.
  • 10Deadman B J,Hopkin MD,Ley SV,et al.The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib,nilotinib and dasatinib[J].Org Biomol Chem,2013,11 (11):1766-1780.

引证文献5

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部